Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases. While conventional chemotherapy has been a cornerstone of treatment, the advent of targeted therapy has revolutionized cancer care. One such breakthrough drug is Gefitinib, a tyrosine kinase inhibitor (TKI) specifically designed to target epidermal growth factor receptor (EGFR) mutations, which play a crucial role in NSCLC...